Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

GSK Gains EU Rights To Lunesta Through Deal With Sepracor

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

GSK will market the sleep aid as Lunivia in Europe upon approval, which is anticipated in the second half of 2008.

You may also be interested in...



Sepracor Reports Positive Data From Lunesta Trial In Generalized Anxiety

Firm may be planning to expand the label for its insomnia drug.

Sepracor Reports Positive Data From Lunesta Trial In Generalized Anxiety

Firm may be planning to expand the label for its insomnia drug.

Sepracor Plans Alvesco, Omnaris Drug Launches Following Acquisition From Nycomed

Sepracor’s 1,600-person sales force will promote the asthma and allergic rhinitis treatments.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS066586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By